COVID-19 neutralizing assays show the downside of not sharing

Finding out which of the COVID-19 vaccines will work at all, let alone best, was not helped by the fact each company chose to measure antibody titers using a different preclinical test. 

The lack of standardization will make it difficult to establish correlates of protection that apply beyond single programs, and serves as an example of the need for greater preclinical harmonization across companies (see “Having Touched the Third Rail of Data Sharing in the Pandemic, Drug Developers Should Hold on Tight”). ...